<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="emmm201910938-fig-0003ev" orientation="portrait" position="float">
 <label>Figure EV3</label>
 <caption>
  <title>Principle of the FcγR assay and correlation between 
   <styled-content style="fixed-case" toggle="no">PR</styled-content>8 FcγR titer and total IgG 
   <styled-content style="fixed-case" toggle="no">ELISA</styled-content> titer
  </title>
  <p>
   <list list-type="simple" id="emmm201910938-list-0010">
    <list-item>
     <label>A</label>
     <p>Scheme of FcγR assay setups used to detect FcγR‐activating antibodies against all viral proteins. MDCKII cells were either infected with influenza virus before pre‐challenge sera and FcγR‐reporter cells were added. Upon activation of the FcγR, IL‐2 is produced within the FcγR‐reporter cell, which is quantified by anti‐IL‐2 ELISA.</p>
    </list-item>
    <list-item>
     <label>B</label>
     <p>Correlation between total influenza IgG ELISA titers and FcγR‐activating antibody titers against PR8 virus. Coefficient of correlation (
      <italic>r</italic>
      <sup>2</sup>) and 
      <italic>P</italic>‐value is shown for each receptor.
     </p>
    </list-item>
    <list-item>
     <label>C, D</label>
     <p>Scheme of FcγR assay setups used to detect FcγR‐activating antibodies against the complete HA protein (C) or the HA‐stalk domain (D). Uninfected MDCKII cells were transfected with wild‐type HA (pAAV‐HA) or a stalk‐only construct (pAAV‐mHL1 + transmembrane region) before pre‐challenge sera and FcγR‐reporter cells were added. Upon activation of the FcγR, IL‐2 is produced within the FcγR‐reporter cell, which is quantified by anti‐IL‐2 ELISA.</p>
    </list-item>
   </list>
  </p>
 </caption>
 <graphic id="nlm-graphic-15" xlink:href="EMMM-12-e10938-g007" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
